Keyphrases
Abemaciclib
37%
Advanced Breast Cancer
100%
Biomarker Profiling
12%
Biomarker-driven Clinical Trials
12%
Bone-only Disease
12%
Cell Modeling
12%
Circulating Tumor Cells
100%
Cox Regression
12%
Cyclin-dependent Kinase 4/6 Inhibitors
12%
Disease Stratification
12%
Drug Development
12%
ECOG Performance Status
12%
Fulvestrant
12%
HER2-negative Metastatic Breast Cancer
12%
HER2-positive
100%
Hormone Receptor-positive
100%
Hypothesis Generation
12%
Liver Involvement
12%
Machine Learning
12%
Metastatic Breast Cancer
12%
Monarch
100%
Multivariable Cox Regression
12%
Nearest Neighbor Classifier
12%
Overall Survival
50%
Progression-free Survival
25%
Retrospective Analysis
100%
Stage IV Disease
12%
Subgroup Analysis
12%
Treatment Effect
12%
Medicine and Dentistry
Abemaciclib
37%
Arm
12%
Biological Marker
37%
Breast Cancer
100%
Circulating Tumor Cell
100%
Clinical Trial
12%
Cyclin-Dependent Kinase 4
12%
Cyclin-Dependent Kinase 6
12%
Diseases
25%
Electrocorticography
12%
Fulvestrant
12%
Hormone Receptor
100%
Metastatic Breast Cancer
25%
Overall Survival
50%
Progression Free Survival
25%
Proportional Hazards Model
25%
Subgroup Analysis
12%
Treatment Effect
12%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
25%
Cyclin-Dependent Kinase 4
25%
Cyclin-Dependent Kinase 6
25%
Electrocorticography
25%
Fulvestrant
25%
Hormone Receptor
100%
K Nearest Neighbor
25%
Overall Survival
100%
Progression Free Survival
50%